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Lay summary: We investigated the incidence of hepatocellular carcinoma (HCC) in HIV/HBV-
coinfected individuals from a large multi-cohort study in Europe. Over 32,673 patient-years, 60 
individuals (1.7%) developed an HCC. The incidence of HCC remained low in patients initiating TDF 
without cirrhosis at an age <46 years. 
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Background and aims: Robust data on hepatocellular carcinoma (HCC) incidence among 
HIV/hepatitis B virus (HBV)-coinfected individuals on antiretroviral therapy (ART) are needed to 
inform HCC screening strategies. We aimed to evaluate the incidence and risk factors of HCC among 
HIV/HBV-coinfected individuals on tenofovir disoproxil fumarate (TDF)-containing ART in a large 
multi-cohort study. 
Methods: We included all HIV-infected adults with a positive hepatitis B surface antigen followed in 
one of four prospective European cohorts. The primary outcome was the occurrence of HCC. 
Demographic and clinical information was retrieved from routinely collected data, and liver cirrhosis 
was defined according to results from liver biopsy or non-invasive measurements. Multivariable 
Poisson regression was used to assess HCC risk factors. 
Results: 3,625 HIV/HBV-coinfected patients, of whom 72% have initiated TDF-containing ART were 
included. Over 32,673 patient-years (py), 60 individuals (1.7%) developed an HCC. The incidence of 
HCC remained stable over time among individuals on TDF, whereas it increased steadily among those 
not on TDF. Among individuals on TDF, the incidence of HCC was 5.9 per 1,000 py (95% confidence 
interval [CI] 3.60-9.10) in cirrhotics and 1.17 per 1,000 py (0.56-2.14) among non-cirrhotics. Age at 
initiation of TDF (adjusted incidence rate ratio per 10 years increase: 2.2, 95% CI 1.6-3.0) and the 
presence of liver cirrhosis (4.5, 2.3-8.9) were predictors of HCC. Among non-cirrhotic individuals, the 
incidence of HCC was above the commonly used screening threshold of 2 cases per 1,000 py only in 
patients aged >46 years at TDF initiation. 
Conclusions:  Whereas the incidence of HCC was high in cirrhotic HIV/HBV-coinfected individuals, it 
remained below the HCC screening threshold in patients initiating TDF without cirrhosis at an age 
<46 years. 
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Hepatitis B virus (HBV) infection is the most important cause of liver cirrhosis and hepatocellular 
carcinoma (HCC) worldwide (1). In high-income settings, between 5 and 10% of HIV-infected 
individuals are coinfected with HBV, which is a major cause of severe morbidity and mortality in this 
population (2). HIV infection accelerates the progression of HBV-related liver disease and mortality is 
higher among HIV/HBV-coinfected individuals compared to HBV-monoinfected ones (3). While the 
incidence of HBV-related HCC is estimated to range between 0.1 and 0.4% per year among non-
cirrhotics and to be above 3% per year among cirrhotics, it is uncertain if the risk of developing HCC is 
different among HIV/HBV-coinfected individuals (4). In fact, many factors which have a profound 
impact on HBV-related HCC incidence, including age, sex, liver cirrhosis, HBV viral load, hepatitis B e 
antigen (HBeAg) and hepatitis delta virus (HDV)-coinfection, are distributed differently among HIV-
infected individuals compared to HIV-uninfected ones (5-8). 
International guidelines recommend the initiation of tenofovir-containing antiretroviral therapy 
(ART) in all HIV-infected individuals with a positive hepatitis B surface antigen (HBsAg). Tenofovir 
disoproxil fumarate (TDF) is very successful in suppressing HBV replication, independent of HIV 
infection, although treatment response seems to be slightly delayed in HIV/HBV-coinfected 
individuals (8-10). Importantly, no clinically relevant HBV-related resistance to TDF has been 
described to date (11). The use of the potent nucleos(t)ide analogs (NAs) TDF and entecavir (ETV) has 
been associated with a reduced incidence of HCC among HBV-infected patients in Europe and Asia 
(12, 13). Among 325 cirrhotic HBV-infected patients treated with TDF or ETV, the HCC incidence rate 
within the first five years (3.22% per year) was higher than that beyond five years of therapy (1.57% 
per year), suggesting a potential decrease in HCC risk with long-term suppression of HBV replication 
(12). Furthermore, recent data from South Korea suggest that HCC incidence is further decreased, 
albeit not eliminated, in the event of HBsAg loss during NAs therapy, also defined as the functional 
cure of HBV infection (14).  
HCC surveillance through six-monthly ultrasound imaging aims at reducing mortality by diagnosing 
small lesions that are potentially curable by resection, ablation or transplantation (4, 15). Whereas 
the natural history of hepatitis C virus (HCV)-related HCC is largely driven by liver cirrhosis, HBV-
related HCC also develops in non-cirrhotic individuals, which makes surveillance strategies more 
complex. Current recommendations for HBV-related HCC surveillance are mainly based on incidence 
estimated in untreated HBV-monoinfected patients. It is generally accepted that screening is cost-
effective in sub-populations with an incidence >0.2%/year, such as individuals with cirrhosis, Asian 
males >40 years, Asian females >50 years and Africans. Among treated HBV-infected Caucasians, the 
recently established PAGE-B score seems to be particularly helpful in evaluating the risk of HCC and 
potential indication for HCC screening (4, 16). However, this score has not been evaluated among 
HIV/HBV-coinfected individuals to date. Furthermore, as the large majority of HIV/HBV-coinfected 
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are expected to have a suppressed HBV viral load on a TDF-containing ART, it is unknown if this large 
patient group would benefit from HCC screening. We explored the long-term incidence of HCC during 
NAs therapy in the largest collaborative study on HIV/HBV-coinfection in Europe to date. In order to 
inform HCC screening strategies among HIV/HBV-coinfected individuals on TDF-containing ART, we 
assessed the risk of HCC in sub-populations categorized by age, sex and the presence of liver 
cirrhosis. 
 
MATERIALS AND METHODS 
Study setting  
Patients from the following four prospective European HIV cohorts were included: The Swiss HIV 
cohort study (SHCS, www.shcs.ch) (17), EuroSIDA (www.chip.dk/Ongoing-Studies/EuroSIDA/About) 
(18), Athena Observational Cohort Study (www.hiv-monitoring.nl/english/) (19), and ANRS CO3 
Aquitaine Cohort (20). Detailed information on demographics, mode of HIV acquisition, risk behavior, 
clinical events, laboratory measurements, viral hepatitis coinfections, and on the full treatment 
history for HBV and HIV infections were collected using standard protocols at registration and at 
intervals of three to six months. Local ethical committees of all participating study sites approved the 
cohort studies and written or verbal consent was obtained from all participants, as appropriate 
according to local regulations.  
Inclusion criteria, definitions and outcomes 
We included all HIV-infected adults with a positive hepatitis B surface antigen (HBsAg) and a 
complete ART history available. Patients were categorized according to the HBV-activity of their ART 
regimen: (i) no active drug, or first generation drugs, such as lamivudine (LAM) or emtricitabine only 
(referred to as the “no TDF group”); or (ii) second-generation drugs, including TDF and ETV (referred 
to as the “TDF group”, as only 35 patients were on ETV). Patients who did not start TDF at any time-
point were grouped together as the incidence of HCC was similar in those on LAM or no HBV therapy, 
according to preliminary analyses in this patient population (21). Individual follow-up was measured 
from the date of inclusion into one of the cohorts until the date of database closure (01.01.2015), 
HCC diagnosis, death, or loss to follow-up, whichever happened first.  
Our primary outcome was the occurrence of HCC at any time-point during follow-up. In all 
participating cohorts, data on causes of death and confirmation of HCC diagnosis were collected on 
standardized case-report forms, using information from medical hospitalizations, imaging studies or 
liver histology from biopsy to inform and validate the diagnosis. Liver cirrhosis was defined primarily 
according to histology reports from liver biopsies or as a liver stiffness measurement (LSM) >11 kPa 
(22). If these two measurements were not available, we classified participants into the group with 
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cirrhosis if the AST-to-platelet ratio index (APRI) was >2.0, as recommended by the World Health 
Organization (22).  
Statistical analyses 
We described demographic and clinical characteristics using absolute numbers and proportions, or 
medians and interquartile ranges (IQR), and compared them between patients in the “TDF group” 
and those in the “non-TDF group” using Chi-square or Mann-Whitney tests, as appropriate. The 
incidence of HCC was described for the full population, and compared between sub-groups according 
to the main demographic and clinical characteristics. Non-parametric cumulative hazard plots were 
used to assess crude risk of HCC across the two HBV treatment groups. In order to predict the 
incidence rate ratio of HCC during therapy for both groups, we fitted a Poisson regression model, 
stratified by cumulative time on therapy. Individuals could contribute follow-up time to different NAs 
if they were switched from one drug to another. 
Among patients on TDF-containing ART, we explored graphically the incidence of HCC according to 
the presence of liver cirrhosis and the PAGE-B score (16). The latter is based only on baseline 
patients’ 
age, sex and platelets, and is reliable score for prediction of the 5-year HCC risk in Caucasian HBV-
infected patients under ETV or TDF. As proposed in the most recent EASL guidelines, we used the 
PAGE-B score cut-off <10 vs. ≥10 (11). We evaluated the association between HCC and potential risk 
factors, including age, sex, time updated CD4 cell counts, probable mode of HIV transmission, 
ethnicity (Caucasian vs. non-Caucasian), hepatitis C virus (HCV) infection, the respective cohort, 
cumulative time off TDF (ie time from inclusion to first TDF-start), and liver cirrhosis, using 
univariable and multivariable Poisson regression analyses. Derived adjusted incidence ratios for HCC 
were shown graphically in a Forest plot. In order to inform HCC screening strategies for HIV/HBV-
coinfected individuals initiating TDF-containing ART, we predicted the cumulative incidence of HCC in 
specific population sub-groups in relation to the widely used incidence threshold for HCC screening 
(2 cases per 1,000 person-years) (15). The sub-groups were selected according to the results of the 
multivariable analyses. Where appropriate, generalized additive models were fitted using restricted 
cubic splines for continuous variables.  
HDV infection and HBeAg-positivity have both been associated with a higher incidence of HCC in 
previous studies (6, 7). To assess the impact of those two characteristics on the incidence of HCC, 
we repeated the main analyses in the cohorts with data available. In order to avoid relevant 
selection bias, we only included cohorts in which more than 60% of their patients had data 
available. To further explore potential differences in results between patients infected with HCV 
and others, we also repeated the analyses after having excluded HIV/HBV/HCV-coinfected 
individuals. All statistical analyses were performed using R (Version 3.4).  
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RESULTS 
Description of study population and overall HCC incidence 
Of 3,625 HIV/HBV-coinfected individuals included, 2,593 (71.5%) had received TDF or ETV during 
follow-up. Overall, 40.3% of the cumulative follow-up time was spent on TDF, 30.5% on LAM only and 
29.2% on ART without HBV activity. Table 1 compares the main characteristics of patients in the “TDF 
group” with those of individuals in the “no TDF group”. Age and sex distribution was similar across 
treatment groups, but individuals from the “no TDF group” were more likely to be Caucasian, 
injection drug users (IDU), and to be HCV-coinfected. Importantly, HIV/HBV-coinfected individuals 
who never initiated TDF had a shorter median follow-up time compared to those on TDF (5 vs. 9.8 
years), and a majority of them had their last follow-up visit before 2009, whereas most patients on 
TDF were still in care at the time of analyses (Table 1). Over 32,673 patient-years (py), 60 individuals 
(1.7%) developed an HCC, resulting in an overall incidence of 1.84 per 1,000 py (95% confidence 
interval [CI] 1.40-2.36). The incidence rate of HCC remained stable over time when patients used TDF 
(aIRR per additional year: 0.95, 95% CI 0.85-1.06, Figure 1), whereas it increased steadily during the 
time patients were not on TDF (aIRR: 1.14, 95% CI 1.07-1.21). The relatively constant incidence of 
HCC during TDF therapy allowed us to assess the long-term HCC risk based on characteristics at the 
time of TDF initiation.  
Incidence of HCC among HIV/HBV-coinfected individuals on TDF and related risk factors 
Overall, 2,593 patients had ever received TDF and their median follow-up time was 9.8 years (IQR 
5.7-14.5). Eighty-four percent of participants in the “TDF group” were male and 54% were men who 
have sex with men (MSM) (Table 1). Liver cirrhosis was diagnosed in 24% of patients on TDF. The 
diagnosis of cirrhosis was made with the use of liver biopsy in 8% of cases, transient elastography 
in 19% of them, and APRI score in the remainder. Their median CD4 cell count at initiation of TDF 
was 332 cells/µl (IQR 190-498) and their median age 37 years (IQR 31-44). Over 3,393 py, 20 cirrhotic 
individuals on TDF developed HCC, (5.90 per 1,000 py, 95% CI 3.60-9.10), whereas the incidence of 
HCC was 1.17 per 1,000 py (95% CI 0.56-2.14) in non-cirrhotic individuals on TDF. The distribution of 
HCC cases in patients on TDF according to cirrhosis status and PAGE-B score is shown in Figure 2. 
Among non-cirrhotic patients with a PAGE-B score ≥10, the incidence of HCC was 1.3 per 1000 py, 
whereas the estimate for non-cirrhotics with a PAGE-B score <10 was 0.8 per 1000 py. Two non-
cirrhotic patients with a PAGE-B score <10 developed an HCC: a 37-year old, non-Caucasian female 
and a 38-year old Caucasian male, both approximately after 5 years of follow-up. At initiation of TDF-
containing ART, only age (aIRR per 10 years increase: 2.2, 95% CI 1.6-3.0) and the presence of liver 
cirrhosis (aIRR: 4.5, 95% CI 2.3-8.9) were significant predictors of the occurrence of HCC (Figure 3, 
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Suppl. Table 1). However, sex (aIRR: 0.7, 95% CI 0.2-2.4, ref: male) and ethnicity (aIRR: 1.6, 95% CI 
0.6-4.6, ref: Caucasian) did not predict HCC incidence.  
As HCC incidence remains approximately constant during follow-up on TDF-containing ART (Figure 1), 
we predicted the risk of developing an HCC after initiation of TDF-containing ART for patients with 
and without cirrhosis, across the age spectrum at time of TDF start (Figure 4). In patients with 
cirrhosis, the incidence was above 2 cases per 1,000 py across the age span. However, among 
patients without cirrhosis, the HCC screening threshold was only crossed in patients aged >46 years 
at initiation of TDF-containing ART. However, the 95% CI included estimates above the incidence of 2 
cases per 1,000 py for all ages at TDF initiation.  
Sensitivity analyses 
In an analysis of 1’035 patients on TDF with HDV serology results available from the SHCS and 
EuroSIDA, including 130 (12.6%) with a positive anti-HDV test, we observed that 6 (4.6%) 
HIV/HBV/HDV-coinfected patients experienced an event of HCC, whereas 11 (1.2%) had an HCC 
event in the HDV-negative group (p=0.01). In multivariable analyses, HDV infection was not 
significantly associated with HCC (aIRR 2.53, 95% CI 0.76-8.46, p=0.13). Furthermore, among 1,571 
patients with available data on HBeAg in the Aquitaine and Athena cohorts, 19/821 (2.3%) HBeAg-
positive individuals developed an HCC, whereas 6/750 (0.8%) HBeAg-negative had this outcome. 
HBeAg and HCC were not associated in multivariable analyses (aIRR 2.17, 95% CI 0.85-5.58, 
p=0.11). Finally, after the exclusion of 490 HCV-coinfected individuals on TDF, we found an 
incidence of HCC of 3.83 (2.19-6.21) per 1000 person-years in the cirrhosis group and 0.74 (0.38-
1.29) in the non-cirrhotic group. The association between liver cirrhosis and HCC remained similar 
to the original analysis in the whole study population (aIRR 5.44, 95% CI 2.45-12.08). 
 
DISCUSSION 
We present HCC incidence estimates from the largest collaborative analysis of HIV/HBV-coinfected 
individuals on currently recommended first-line NAs to date. Among over 2,500 patients on TDF or 
ETV, the incidence of HCC was 5.9 per 1,000 py in cirrhotic patients and 1.2 per 1,000 py among 
those without cirrhosis. After the initiation of TDF, the incidence of HCC remained stable over time, 
suggesting that an assessment of HCC risk at TDF start would be adequate to inform long-term 
individual HCC screening strategies. Our results show that HIV/HBV-coinfected patients initiating 
TDF-containing ART without cirrhosis at an age <46 years remain at an HCC risk below 2 per 1,000 py, 
which is generally accepted as the threshold below which screening is not recommended. However, 
our findings highlight the need to better understand HCC risk factors in non-cirrhotic patients as the 
risk of HCC was not zero in this category, even in patients with a low risk based on the PAGE-B score. 
Our results also provide estimates for individualized decisions on HCC screening in non-cirrhotics.  
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In our study, the incidence of HCC remained stable during TDF therapy, in line with the results from a 
large multi-center European study of HBV-monoinfected individuals (12). In contrast, incidence in 
those without TDF increased steadily over time. Our results justify the approach of evaluating the 
HCC risk at the time of initiation of potent NAs therapy, and to decide on a surveillance strategy 
based on this assessment. Papatheodoridis et al. showed a clear decrease in HCC incidence after five 
years of NAs therapy among patients with liver cirrhosis. Unfortunately, we were unable to explore 
the presence of such a trend in our cohort of HIV/HBV-coinfected individuals due to the limited 
number of events.  
As expected, the incidence of HCC among cirrhotic patients was above 2 cases per 1,000 py, 
independently of age at TDF start. In comparison, HCC incidence among non-cirrhotics was lower, 
even though the upper margin of the confidence interval was above the proposed screening 
threshold in all age groups. In the absence of cirrhosis, HCC risk seems to be driven by specific risk 
factors, including age at TDF start. In a multi-country cohort of HBV-monoinfected Caucasians, age 
was an important risk factor of HCC overall, while male sex was a significant predictor in non-
cirrhotics only (23). Several specificities of our study population may explain some of the differences 
between our results and those from cohorts of HBV-monoinfected individuals, including the absence 
of an association between sex and HCC. Our study only included HIV-infected individuals, one-half of 
whom were MSM with generally good access to health-care services. Furthermore, >20% of our 
patients were of non-Caucasian origin. As the epidemiology of HCC is expected to be different in this 
sub-population, especially if exposed to other risk factors such as aflatoxin, longitudinal data from 
HCC screening programs from sub-Saharan Africa are urgently needed (24). 
As HCC screening is costly and can lead to unnecessary interventions, low-risk groups in which 
surveillance is not necessary need to be defined. The PAGE-B score, recently developed in a 
European multi-country cohort study and based on age, sex and platelet count, was shown to 
perform well in selecting patients with low risk for HCC (16). Among patients with a score <10, the 
cumulative incidence of HCC was 0%, both in the derivation and the validation datasets. As a 
consequence, this score was integrated into decision algorithms for recommendations on HCC 
surveillance in HBV-monoinfected populations without cirrhosis (4). In our study, two non-cirrhotic 
patients with a low PAGE-B score (<10), including one Caucasian, developed an HCC after 
approximately five years of follow-up. Although the numbers are low, these findings contrast with 
data from HBV-monoinfected cohorts. Previous experience with validating predictive scores derived 
from HBV-monoinfected cohorts has shown that similar proficiency can generally not be expected in 
HIV-infected populations. For instance, non-invasive scores used to predict liver fibrosis among HBV-
infected individuals were not shown to be adapted for HIV-infected populations (25). In order to 
achieve a decent risk stratification of HIV/HBV-coinfected populations, a thorough assessment of the 
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proficiency of the PAGE-B score in this population is essential, and the potential development of 
another score, better adapted to this specific patient population must be evaluated.  
We provide robust estimates on HCC incidence from a large, multi-country study of HIV/HBV-
coinfected individuals in Europe. As current recommendations for HBV-related HCC screening are 
based on estimates from HBV-monoinfected populations, our data will inform clinical monitoring 
strategies of HIV/HBV-coinfected patients and shape future research questions in the field. 
Unfortunately, we did not have access to systematically measured HBV DNA values during TDF-
containing ART. Although previous studies have shown high rates of HBV suppression on TDF-
containing ART, we cannot exclude that a small proportion of patients had a sustained viral 
replication, a well-known risk factor for the development of HCC (10, 26, 27). The limited availability 
of data on hepatitis delta infection, as well as on HBeAg serology, was an additional limitation to our 
study, as both markers are drivers of HCC and liver-related mortality among HBV-infected patients 
(6, 7). However, in sensitivity analyses limited to cohorts with data available, we did not find 
significant associations between these markers and HCC. Finally, although it would have been 
important to analyze the risk of HCC in specific sub-populations of non-cirrhotics to guide HCC 
surveillance strategies, our sample size and number of events were low, especially in certain patient 
groups such as women and individuals of African origin.  
 
CONCLUSIONS 
As most HIV/HBV-coinfected individuals currently in care in high-income countries are non-cirrhotic 
with a suppressed HBV viral load on a TDF-containing regimen, it is of major importance to have 
reliable HCC incidence estimates to guide HCC surveillance. Our data suggest that the incidence of 
HCC is low in this group of patients, especially if TDF is initiated early during the course of disease. 
However, HCC events still occur in these patients and it will be important to further assess risk 
factors and derive predictive scores for HCC, tailored to HIV/HBV-coinfected populations. 
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Table 1: Demographic and clinical characteristics of patients, by HBV-active treatment group 
(n=3,625) 
 No TDF TDF P-value 
 n=1,032 n=2,593  
Median age in years (IQR) 35 [29, 42] 37 [31, 44] 0.5 
Female sex (%) 179 (17) 414 (16) 0.4 
Non-caucasian (%) 136 (13) 588 (23) < 0.001 
HIV transmission group (%)   < 0.001 
Heterosexual 235 (23) 726 (28)  
IDU 289 (28) 299 (12)  
MSM 422 (41) 1401 (54)  
Other 
Missing 
25 (2) 
61 (6) 
51 (2) 
116 (4) 
 
HCV co-infection (%) 352 (34) 490 (19) < 0.001 
Liver cirrhosis (%) 145 (14) 620 (24) < 0.001 
Median baseline CD4 count in 
cells/µl (IQR) 
310 (159-503) 332 (190-498) 0.02 
Cohort (%)   < 0.001 
      Aquitaine 291 (28) 319 (12)  
      Athena 236 (23) 1146 (44)  
      EuroSIDA 276 (27) 553 (21)  
      SHCS 229 (22) 575 (22)  
Median follow-up in years (IQR) 5.0 (1.9-9.0) 9.8 (5.7-14.5) < 0.001 
Calendar years of last visit (IQR) 2008 (2002-2014) 2014 (2014-2015) < 0.001 
HCV: hepatitis C virus infection, MSM: men who have sex with men, IDU injection drug use, SHCS: Swiss  
HIV Cohort Study, TDF: tenofovir disoproxil fumarate 
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Figure 1: HCC Incidence rate ratio, stratified by cumulative time on HBV therapy regimens 
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Figure 2: Distribution of HCC cases among patients on TDF-containing ART, by cirrhosis status and 
PAGE-B score at TDF start. Dots represent cases of HCC 
 
A. Non-cirrhotics (N=1,479) 
 
 
 
B. Cirrhotics (N=577) 
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Supplementary table 1: Multivariable analysis of HCC risk factors among HIV-infected individuals on 
TDF during follow-up (n=2,593) 
 
 Univariable P-value Multivariable P-value 
   (N = 2,474)  
Age in years (10 yr. steps) 1.9 [1.4, 2.1] <0.001 2.2 [1.6, 3.0] <0.001 
Female sex 0.6 [0.2, 1.8] 0.4 0.7 [0.2, 2.4] 0.6 
Non-Caucasian 0.8 [0.3, 1.9] 0.6 1.6 [0.6, 4.6] 0.2 
HIV transmission group  0.3  0.3 
Heterosexual/MSM/other 1.0 (reference)  1.0 (reference)  
IDU 1.9 [0.9, 3.8] 0.09 2.8 [0.9, 9.4] 0.09 
HCV co-infection 1.4 [0.7, 2.8] 0.3 0.8 [0.3, 2.4] 0.7 
Liver cirrhosis 4.5 [2.4, 8.4] < 0.001 4.5 [2.3, 8.9] <0.001 
Time updated     count in cells/µl 
(50 cells steps) 
0.8 [0.6, 1.2] 0.3 0.8 [0.6, 2.8] 0.3 
Cohort  0.9  0.7 
      Aquitaine 1.0 (reference)  1.0 (reference)  
      Athena 1.2 [0.5, 3.2] 0.7 0.8 [0.3, 2.4] 0.7 
      EuroSIDA 1.0 [0.3, 2.8] 0.9 0.5 [0.2, 1.6] 0.3 
      SHCS 1.1 [0.4, 3.0] 0.9 0.8 [0.3, 2.2] 0.6 
Cumulative time off TDF (2 yr. steps)* 1.0 [0.9, 1.1] 0.6 1.0 [0.8, 1.1] 0.5 
MSM: men who have sex with men, IDU injection drug use, HCV: hepatitis C virus infection, SHCS: Swiss  
HIV Cohort Study, TDF: tenofovir disoproxil fumarate. 
*The cumulative time off TDF represents the time between study inclusion and initiation of TDF  
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Figure 3: Multivariate adjusted Incidence ratios for HCC for those on TDF during their follow-up, 
based on characteristics at initiation of TDF (N = 2473) 
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Figure 4: Incidence of hepatocellular carcinoma among HIV/HBV co-infected individuals at 
initiation of TDF-containing ART (N=2,537). Dotted line represents the recommended screening 
threshold; shaded area represents the 95% CI. Independent variables: restricted cubic spline fitted 
for age, cirrhosis, time updated CD4 and interaction terms between age and cirrhosis, and CD4 and 
cirrhosis.  
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Highlights for JHEPAT-D-18-02127 
 
 
 Over 32,673 patient-years (py) of follow-up, 60 (1.7%) HIV/HBV-coinfected individuals 
developed an incident episode of hepatocellular carcinoma (HCC)  
 Among 2,593 patients on TDF-containing antiretroviral therapy, the incidence of HCC 
was 5.90 per 1,000 py (95% CI 3.60-9.10) in cirrhotics and 1.17 per 1,000 py (95% CI 
0.56-2.14) in non-cirrhotics.  
 The incidence of HCC remained below the recognized screening threshold of 2 cases 
per 1,000 py in non-cirrhotics initiating TDF when younger than 46 years. 
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